Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) generates a steady flow of news as a fully integrated, commercial-stage biotechnology company with both marketed products and a broad development pipeline. News coverage for Tonix often centers on its FDA-approved fibromyalgia treatment TONMYA, its acute migraine products Zembrace SymTouch and Tosymra, and updates on clinical and regulatory milestones across central nervous system, immunology, rare disease and infectious disease programs.
Investors following TNXP news can expect announcements on commercial launches, market access decisions, and distribution arrangements for TONMYA, as well as prescription trends and formulary placements for its migraine therapies. The company also regularly reports progress on TNX-102 SL in indications such as acute stress-related conditions and major depressive disorder, including IND clearances and the design of potentially pivotal Phase 2 studies.
Tonix’s immunology and infectious disease work contributes additional news items, including collaborations with academic centers like Massachusetts General Hospital for TNX-1500 in kidney transplantation, and development plans for TNX-4800, a monoclonal antibody designed for seasonal prevention of Lyme disease. Licensing transactions, such as the acquisition of TNX-4900 for chronic neuropathic pain from Rutgers University, and government-supported projects like the DTRA-backed antiviral TNX-4200, are also common themes in company press releases.
This TNXP news page aggregates company-issued updates and related coverage so readers can quickly review developments in Tonix’s commercial operations, clinical pipeline, financing activities, and strategic collaborations. For investors and observers tracking biotech catalysts, revisiting this page provides a concise way to monitor how Tonix’s programs and capital markets actions evolve over time.
Tonix Pharmaceuticals (Nasdaq: TNXP) reported its Q3 2021 financial results, revealing cash and cash equivalents of approximately $183 million, an increase from $77.1 million at year-end 2020. Significant R&D advancements include the operationalization of its Research and Development Center in Frederick, MD, and the build-out of its Advanced Development Center in New Bedford, MA, aimed at accelerating COVID-19 and infectious disease programs. Planned trials for TNX-2100 and TNX-1300 are expected to commence this quarter, contributing to the company’s expanding pipeline.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present at BIO-Europe 2021, taking place virtually from October 25-28, 2021. The presentation will be accessible on demand for registered participants. Tonix focuses on developing treatments for human diseases, particularly in immunology and central nervous system disorders. Their product candidates include TNX-1800, a COVID-19 vaccine, and TNX-3500, an antiviral for acute COVID-19. Tonix aims to start human trials for TNX-2100, an in vivo diagnostic for T cell immunity, in Q4 2021.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced the opening of its new 48,000 square foot research and development center in Frederick, Maryland, on October 18, 2021. The center aims to enhance its infectious disease pipeline, particularly for COVID-19 and other pathogens. U.S. Senator Ben Cardin and Congressman David Trone will attend the ribbon-cutting event. Tonix plans to develop vaccines and antiviral therapeutics, utilizing its recombinant pox virus platform technology to respond quickly to emerging pandemic threats. The facility will operate as a biosafety level-3 lab to conduct research on live pathogens.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that Dr. Seth Lederman will participate in a panel discussion at the A.G.P. Fall Virtual Biotech & Specialty Pharma Conference on October 13, 2021, at 12:00 p.m. ET. The panel, titled "Long COVID & COVID variants - How to tackle the still ongoing pandemic", will be moderated by analyst Jim Molloy. Tonix's portfolio includes candidate therapies for COVID-19 and Long COVID, such as the vaccine candidate TNX-1800 and the antiviral drug TNX-3500, both in various stages of development.
Tonix Pharmaceuticals (Nasdaq: TNXP) has acquired a new research and development center in Frederick, Md., which spans approximately 48,000 square feet. This facility will enhance the company's capabilities in developing vaccines and antiviral drugs against COVID-19 and other infectious diseases. Key projects include TNX-1800, a COVID-19 vaccine, TNX-801 for smallpox and monkeypox, and TNX-3500, an antiviral for COVID-19. The center is currently BSL-2 certified, with plans to upgrade to BSL-3 for handling live pathogens.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced the acceptance of an oral presentation at the ACR Convergence 2021, scheduled for November 6, 2021. The presentation will focus on TNX-102 SL, highlighting positive results from a Phase 3 trial for fibromyalgia treatment. The company's pipeline also includes candidates for COVID-19, such as TNX-1800, slated for Phase 1 studies in early 2022, and TNX-3500, which is in pre-IND development. Tonix aims to address various health challenges, particularly in immunology and CNS disorders.
Tonix Pharmaceuticals (Nasdaq: TNXP) has expanded its collaboration with Columbia University to study immune responses to COVID-19. This research targets healthy volunteers with previous infections or those asymptomatic, focusing on T cell and antibody responses. Principal investigators Dr. Ilya Trakht and Dr. Sergei Rudchenko aim to identify biomarkers for protective immunity, potentially leading to tailored vaccines and monoclonal antibody therapeutics. Tonix's lead vaccine candidate, TNX-1800, is advancing toward a Phase 1 study, expected to begin in early 2022.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that its President and CEO, Seth Lederman, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 2:00 p.m. ET. Investors can arrange virtual meetings with the management. A webcast of the presentation will be accessible on the Tonix website under the Investors section, with a replay available for 90 days. Tonix focuses on developing treatments for various conditions, including COVID-19, utilizing a platform of innovative product candidates.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced progress on its live virus vaccine TNX-1800, designed to provide long-lasting T cell immunity against COVID-19. Following a pre-IND meeting with the FDA, the company received guidance on the Phase 1 study, expected to commence in H1 2022. TNX-1800 demonstrated efficacy in animal studies, effectively protecting upper and lower airways from SARS-CoV-2. The vaccine, based on horsepox, may offer advantages like scalability and reduced cold chain requirements compared to existing mRNA vaccines.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that its President and CEO, Seth Lederman, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Interested investors may arrange virtual meetings with management. A webcast of the presentation will be available on-demand starting September 13, 2021, at 7:00 a.m. on the Tonix website, with a replay accessible for 90 days. Tonix focuses on developing therapies in CNS and immunology, including lead candidates for fibromyalgia and COVID-19 vaccines.